Research Highlights | Published:

Cancer immunotherapy

Gene-edited cells fight cancer

Nature volume 539, pages 332333 (17 November 2016) | Download Citation

Immune cells engineered to target cancer could provide an off-the-shelf therapy if results in mice can be replicated in people.

Previous work has shown that engineered T cells called CAR-T cells can be taken from a patient and modified to kill some types of tumour, but the supply can be limited. To make a more reliable, universal source of donor cells, Carl June, Yangbing Zhao and their colleagues at the University of Pennsylvania in Philadelphia used the genome-editing tool CRISPR–Cas9 to tweak human CAR-T cells. They disabled two proteins that can trigger immune rejection of donor T cells, resulting in a reduced reaction from the immune system when the cells were used in mice.

The team also disrupted a protein called PD-1, which normally holds immune responses in check. The cells slowed the growth of human tumours implanted into mice. Further testing of immune responses should be carried out in non-human primates, the authors say.

Clin. Cancer Res. (2016)

About this article

Publication history





    By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

    Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing